GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR Regulation. With 3,7 Mio packs, equivalent to more than 51 Mio of standard units sold through our licensees in 34 countries during 2023, the Tasectan franchise is already [...]
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants. XILAPLUS® is a class III medical device and complies with the [...]
Elena D Serban & Mihai Manolache; Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Publication of a retrospective, observational study on Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis. Aim: To evaluate the effectiveness and safety of gelatin tannate [...]
Maurizio Mennini1,Carlo Tolone, Antonella Frassanito, Fabio Midulla3, Salvatore Cucchiare, Marina Aloi. Paediatr Drugs. 2016 Dec 20. doi: 10.1007/s40272-016-0207-z Background: Oral rehydration therapy is the recommended treatment for acute childhood gastroenteritis. The aim of this study was to assess the efficacy and safety of gelatin tannate plus oral rehydration compared with [...]
Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann Pediatr Child Health 2020; 8(6): 1194. Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann [...]
Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal [...]
Int. J. Mol. Sci. 2018, 19(3), 673 Abstract Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as [...]
TASECTAN® launched in Croatia by JGL. Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop. TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and [...]
Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée. XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies. It acts by forming a film which protects the intestinal mucosa, reducing the [...]
Aloi M, Mennini M. J Comp Eff Res. 2018 Nov 22. Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis. AIM: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis. METHODS: A comprehensive literature search [...]